Literature DB >> 22873189

Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.

Sharon Stancliff1, Herman Joseph, Chunki Fong, Terry Furst, Sandra D Comer, Perrine Roux.   

Abstract

The aim of this pilot study was to assess the effectiveness of buprenorphine/naloxone (BUP/NX) among marginalized, opioid-dependent individuals in terms of retention in and cycling into and out of a harm-reduction program. This pilot study enrolled 100 participants and followed them from November 2005 to July 2008. The overall proportion of patients retained in the program at the end of 3, 6, 9, and 12 months was 68%, 63%, 56%, and 42%, respectively. This pilot study demonstrated that BUP/NX could be successfully used to treat marginalized heroin users.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22873189      PMCID： PMC3620719          DOI： 10.1080/10550887.2012.694603

Source DB:  PubMed          Journal:  J Addict Dis        ISSN： 1055-0887


  36 in total

1.  Treatment retention and 1 year outcomes for residential programmes in England.

Authors:  M Gossop; J Marsden; D Stewart; A Rolfe
Journal:  Drug Alcohol Depend       Date:  1999-12-01       Impact factor: 4.492

2.  Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health.

Authors:  Perrine Roux; Claudia Tindall; Lionel Fugon; Janet Murray; Suzanne K Vosburg; Phillip Saccone; Maria A Sullivan; Jeanne M Manubay; Ziva D Cooper; Jermaine D Jones; Richard W Foltin; Sandra D Comer
Journal:  Addiction       Date:  2012-03       Impact factor: 6.526

3.  Buprenorphine in the treatment of opiate dependence.

Authors:  Donald R Wesson; David E Smith
Journal:  J Psychoactive Drugs       Date:  2010-06

4.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

Authors:  J P Moatti; M P Carrieri; B Spire; J A Gastaut; J P Cassuto; J Moreau
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

5.  Buprenorphine for opiate addiction: potential economic impact.

Authors:  R Rosenheck; T Kosten
Journal:  Drug Alcohol Depend       Date:  2001-08-01       Impact factor: 4.492

6.  Post-marketing surveillance of methadone and buprenorphine in the United States.

Authors:  Nabarun Dasgupta; Elise J Bailey; Theodore Cicero; James Inciardi; Mark Parrino; Andrew Rosenblum; Richard C Dart
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

7.  Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.

Authors:  Mark L Kraus; Daniel P Alford; Margaret M Kotz; Petros Levounis; Todd W Mandell; Marjorie Meyer; Edwin A Salsitz; Norman Wetterau; Stephen A Wyatt
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

8.  Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program.

Authors:  David Hersh; Sherri L Little; Alice Gleghorn
Journal:  J Psychoactive Drugs       Date:  2011 Apr-Jun

9.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

Review 10.  Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach.

Authors:  Philippe Bourgois; Alexis Martinez; Alex Kral; Brian R Edlin; Jeff Schonberg; Dan Ciccarone
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069
View more
  32 in total

1.  Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.

Authors:  Aaron D Fox; Adam Chamberlain; Taeko Frost; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

2.  A New Way Forward in the Emergency Department.

Authors:  Evan S Schwarz; JoAn R Laes; Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2019-07-05

3.  Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.

Authors:  Pauline Voon; Ronald Joe; Christopher Fairgrieve; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2016-07-11

4.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

5.  Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Authors:  Jermaine D Jones; Jared J Atchison; Gabriela Madera; Verena E Metz; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

6.  No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.

Authors:  Jermaine D Jones; Aimee Campbell; Verena E Metz; Sandra D Comer
Journal:  Addict Behav       Date:  2017-03-09       Impact factor: 3.913

7.  I heard about it from a friend: assessing interest in buprenorphine treatment.

Authors:  Aaron D Fox; Pooja A Shah; Nancy L Sohler; Carolina M Lopez; Joanna L Starrels; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

8.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

9.  Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.

Authors:  Pablo K Valente; Angela R Bazzi; Ellen Childs; Peter Salhaney; Joel Earlywine; Jennifer Olson; Dea L Biancarelli; Brandon D L Marshall; Katie B Biello
Journal:  Int J Drug Policy       Date:  2020-09-07

10.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.